A Phase 2a, Open-label, Single-arm, Multi-center Study to Evaluate the Efficacy and Safety of LCB01-0371 (Delpazolid) as Add-on Therapy in Patients With Refractory Mycobacterium Abscessus Complex Pulmonary Disease

The purpose of this study is to evaluate the efficacy and safety of delpazolid add-on therapy in Patients with Refractory Mycobacterium abscessus Complex Pulmonary disease

开始日期2024-01-16

申办/合作机构

LigaChem Biosciences, Inc.

NCT05225558

/ Terminated临床2期

A Multicenter, Double-blinded, Randomized, Parallel Design, Phase IIa Clinical Trial to Evaluate the Efficacy, Safety and PK of LCB01-0371 With Vancomycin Versus Vancomycin Monotherapy in Patients With MRSA Bacteremia

The objectives of this study is to exploratory whether Vancomycin + Delpazolid is more effective to the standard of treatment (Vancomycin)/ for hospitalized adults with MRSA bacteraemia.

开始日期2022-04-26

申办/合作机构

LigaChem Biosciences, Inc.

NCT04550832

/ Completed临床2期

A Phase IIb, Open Label, Randomized Controlled Dose Ranging Multi-Center Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Exposure-Response Relationship of Different Doses of Delpazolid in Combination With Bedaquiline Delamanid Moxifloxacin in Adult Subjects With Newly Diagnosed, Uncomplicated, Smear-Positive, Drug-sensitive Pulmonary Tuberculosis

This trial is to describe the safety, tolerability and exposure-toxicity relationship of Depazolid given over 16 weeks, in combination with standard-dose Bedaquiline, Delamanid and Moxifloxacin, compared to standard-dose Bedaquiline, Delamanid and Moxifloxacin alone

开始日期2021-10-28

申办/合作机构

LigaChem Biosciences, Inc.

[+3]

100 项与 Delpazolid 相关的临床结果

登录后查看更多信息

100 项与 Delpazolid 相关的转化医学

登录后查看更多信息

100 项与 Delpazolid 相关的专利（医药）

登录后查看更多信息

126

项与 Delpazolid 相关的文献（医药）

2025-08-01·JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB

Article

作者: Narunsky, Kim ; Wallis, Robert ; Bateson, Anna ; Minja, Lilian Tina ; Semvua, Hadija ; Stoycheva, Krista ; te Brake, Lindsey ; Grobusch, Martin P ; Adegbite, Bayode Romeo ; Kirenga, Bruce ; Gillespie, Stephen ; Paramo, Laura ; Sithole, Jane ; Beattie, Trevor ; McHugh, Timothy ; Koele, Simon E ; Hoelscher, Michael ; Mtafya, Bariki ; Sabi, Issa ; Nliwasa, Mariott ; Sam, Noel ; Makkan, Heeran ; Wagnerberger, Larissa ; Manyama, Christina ; Svensson, Elin ; Aldana, Brian ; Hoffmann, Larissa ; Liyoyo, Alphonce ; Friedrich, Sven ; Churchyard, Gavin ; Gong, Xue ; McHugh, Timothy D ; Noreña, Ivan ; Adegnika, Ayola Akim ; Lutchmun, Wandini ; Razid, Alia ; Wildner, Leticia Muraro ; Mouhdad, Chaima ; Dreisbach, Julia ; Dierig, Alexa ; Mangu, Chacha ; Crook, Angela ; Reither, Klaus ; de Jager, Veronique ; Aldana, Brian H ; Kibiki, Gibson ; Mhimbira, Francis ; Mbeya, Benno ; Svensson, Elin M ; Sebe, Modulakgotla ; Sloan, Derek J ; Aarnoutse, Rob ; Madikizela, Namhla ; Gross-Demel, Petra ; Khosa, Celso ; Minja, Lilian T ; Te Brake, Lindsey ; Wildner, Leticia ; Sanne, Ian ; Koele, Simon ; Solanki, Priya ; Phillips, Patrick ; Hunt, Robert ; Jarchow-MacDonald, Anna ; Mtweve, Cyprian ; Peter, Daud D ; Aarnoutse, Rob E ; Schildkraut, Jodie ; Jugheli, Levan ; Boeree, Martin ; Sabiiti, Wilber ; Rassool, Mohammed ; Sasamalo, Mohamed ; Mukoka, Madalo ; Grobusch, Martin Peter ; Sloan, Derek ; Mdluli, John ; Mokaba, Lucia ; Phillips, Patrick P J ; Dawson, Rodney ; Ntinginya, Nyanda Elias ; Mpagama, Stellah ; Huglin, Beno ; Stemkens, Ralf ; Timana, Isabel ; Diacon, Andreas ; Norena, Ivan ; Rojas-Ponce, Gabriel ; Heinrich, Norbert ; Zumba, Tresphory

Abstract:

Introduction:

Many drugs for the treatment of TB prolong the QTc interval, which is associated with an increased risk of developing a life-threatening arrhythmia known as torsades de pointes. Sutezolid and delpazolid are novel oxazolidinones with demonstrated bactericidal activity. We aimed to assess the effects of sutezolid or delpazolid co-administered with bedaquiline, delamanid and moxifloxacin on the QTcF interval (Fridericia’s correction). Furthermore, we developed a population pharmacodynamic model to assess the effects of drug exposure on the QTcTBT interval (TB-specific correction).

Methods:

Participants were randomized to receive standard-dose bedaquiline, delamanid and moxifloxacin with varying doses of either sutezolid (no sutezolid, 600 mg daily, 1200 mg daily, 600 mg twice daily, 800 mg twice daily) or delpazolid (no delpazolid, 400 mg daily, 800 mg daily, 1200 mg daily, 800 mg twice daily). The QTc interval was determined using weekly ECG assessments.

Results:

Data from 149 participants, yielding 2373 ECG observations were available for analysis. Nine participants (6.0%) experienced a Grade 3 QTcF prolongation as defined by the Common Terminology Criteria for Adverse Events v5.0. The population pharmacodynamic model predicted a 13.2 ms (95% CI: 10.9–15.3) increase of the QTcTBT in the first week of treatment, but no further increase after that. The exposure of bedaquiline’s M2 metabolite was found to drive part of the QTcTBT. No exposure–response relationship was identified for the other drugs investigated.

Conclusions:

The drug regimens containing standard doses of bedaquiline, delamanid and moxifloxacin, and varying doses of sutezolid or delpazolid were not found to pose a high cardiac risk in a population without further QTc-relevant risk factors. However, close monitoring of the QTc interval remains essential in patients with TB treated with combination drug therapy with known QTc-prolonging drugs.

2025-08-01·TALANTA

Zirconium nanoparticles decorated chitosan@hematoxylin/pencil graphite as a novel voltammetric sensor for monitoring of linagliptin/dapagliflozin co-therapy

Article

作者: Darwish, Ibrahim A ; Hosny, Noha M

A fixed dose combination of linagliptin (LNG) and dapagliflozin (DPZ) was recently approved as a better therapeutic approach than monotherapy of type 2 diabetes mellites. To support the bioequivalence studies of LNG/DPZ combination, and refining of its pharmacokinetics and safety profile, a sensitive and convenient analytical method is required for their simultaneous quantitation in plasma samples. This research describes the construction of an innovative electrochemical sensor and its employment in the development of the first square wave voltammetric (SWV) method for the concurrent quantitation of LNG/DPZ in plasma samples. The sensor (Zr_NPs-CHIT@HEM/PGE) was fabricated using hematoxylin (HEM) stain platform on a pencil graphite electrode (PGE) surface, where chitosan (CHIT) and zirconium nanoparticles (Zr_NPs) were overlayed on. This sensor was characterized by cyclic voltammetry, scanning electron microscopy, and electrochemical impedance spectroscopy. Subsequently, the constructed sensor is employed for electro-oxidation and SWV estimation of LNG/DPZ combination in their pure forms and in plasma. The suggested procedure was optimized, and its analytical performance was validated. The linear ranges were 0.17-5.8 and 1.5-52.5 nM for LNG and DPZ, respectively. The quantitation limits were 0.15 and 1.34 nM for LNG and DPZ, respectively. Acceptable accuracy and precision were confirmed (98.63-101.59 % ± 0.79-2.22 %). The selectivity of the method for simultaneous analysis of LNG/DPG in presence of common interfering substances was confirmed as the recovery values of the analytes were in the range of 96.19-99.52 %. The proposed SWV method was successfully applied to the quantitation of both LNG and DPZ in spiked and in real plasma samples obtained from rabbits receiving LNG/DPZ combination. The Zr_NPs-CHIT@HEM/PGE sensor constructed and employed in this study demonstrated exceptional graphite distinctive characteristics, such as high surface area, remarkable electrical conductivity, rapid electron mobility at room temperature, and ease of fabrication/functionalization. Additionally, the use of Zr_NPs for construction provided exceptional opportunities for the design of the sensor and enhanced its electrochemical sensing performance. Furthermore, the significant electrochemical properties of both CHIT and HEM used in the nanocomposite of the sensor demonstrated superior electrocatalytic behaviour for the differential electro-oxidation of LNG and DPZ. The proposed SWV method represents the prototype of electrochemical techniques for the concurrent quantitation of LNG and DPZ in plasma samples. This method would have great value to support the pharmacokinetic studies, therapeutic drug monitoring, and refining the safety profile of fixed-dose combined therapy with LNG/DPZ.

2025-07-09·ACS Applied Materials & Interfaces

Establishing Structure–Activity Relationships in Heterogeneous Catalysis of Three-Component Organic Coupling Reactions by Lewis Acidic Metal Sites and Polar Moieties

Article

作者: Mandal, Sanjay K. ; Bhambri, Himanshi

The postpandemic surge in demand for antimicrobial drugs has accelerated the customization of suitable catalysts, fostering a synergy between their structure and activity in promoting the multicomponent organic coupling reactions. In this work, we have successfully constructed two new polar metal-organic frameworks, viz., Co-bpaipa and Ni-bpaipa, where bpaipa^2- = 5-(bis(pyridin-2-ylmethyl)amino)isophthalate, embedded with catalytically active Co/Ni Lewis acidic metal sites and polar moieties (such as O/N heteroatoms) for a critical evaluation of their role in the synthesis of an important category of antimicrobial drugs, oxazolidinones, from a three-component coupling reactions. Both frameworks feature a rare 2D fes topology and possess high thermal (up to 380 °C) and water stability. Microscopic analysis revealed block- and octagon-shaped surface images of Co and Ni analogs, respectively, at the micrometer scale. Their chemical state and elemental composition were further examined using X-ray photoelectron spectroscopy. For the solvent-free synthesis of 2-aryl oxazolidinones, the use of CO₂ gas as a direct feedstock ensures a sustainable process that also involves epoxides and aromatic amines. The vital aspect of this study is to optimize conditions that are critical for high yields of products under a comparatively milder temperature, a lower catalyst loading, and a shorter reaction time. Interestingly, depending on the metal center, the epoxide-to-aniline ratio influences the formation of oxazolidinones such that the maximum conversion (∼90%) is obtained with Co-bpaipa and Ni-bpaipa using 3:1 and 1:1 ratios, respectively. Such an outcome through a comparison of two catalysts with a difference in the single metal site conducted for the first time is fully supported by investigating the nature and strength of interactions between the reactants and catalysts through comprehensive theoretical simulations, including QTAIM and CBMC analysis. A wide spectrum of substrates with diverse electronic, steric, and polarizing effects is tested to obtain bioactive precursors, particularly tedizolid and delpazolid, achieving high conversion rates (65-94%) and turnover numbers. The postcatalysis analysis of both Co-bpaipa and Ni-bpaipa demonstrates their structural stability and nonleachability, even after multiple catalytic runs.

项与 Delpazolid 相关的新闻（医药）

2023-03-24

·佰傲谷BioValley

甲贝视野 | 越了解，越无畏，这一份结核病手册请查收

导语2023年3月24日是第28个世界防治结核病日。世界卫生组织（WHO）发布的主题为：“是的！我们可以终止结核病（YES! WE CAN END TB）！”，旨在呼吁各国广泛参与，共同终结结核病的流行。我国疾病预防控制局最新发布的宣传主题“你我共同努力，终止结核流行”。正文感染结核病的人大多脸色苍白，身形消瘦，咳嗽严重，故西方称之为“白色瘟疫”。历史上三国著名军事家诸葛亮就是脊椎结核，所以年纪轻轻就是扶杖而行，最后死于吐血。红楼梦中的女主角林黛玉是肺结核，最后吐血而亡。波兰著名作曲家肖邦，俄国批判现实主义作家契诃夫，德国著名文学家席勒，美国诗人梭罗，以及英国诗人雪莱——他曾向世人呼喊“冬天来了，春天还会远吗”，自己却未能看到人类战胜肺结核的春天。中国近代文学大家鲁迅先生，也是身患肺结核最后早逝。今天，我们一起来了解下什么是结核病，如何预防、诊断和治疗这种疾病，以及关于它的最新研究进展。1.结核病和结核杆菌结核杆菌(Mycobacterium Tuberculosis,MTB))是德国细菌学家Robert Koch于1882年3月24日发现的，它是引起人和动物结核病的病原菌。并将其分为人型、牛型、鸟型和鼠型4型，其中人型菌是人类结核病的主要病原体。图1.结核病常见临床表现肺结核(Tuberculosis，TB)就是主要由人型结核杆菌侵入肺脏后引起的一种具有强烈传染性的慢性消耗性疾病。常见临床表现为咳嗽、咯痰、咯血、胸痛、发热、乏力、食欲减退等局部及全身症状。肺结核90％以上是通过呼吸道传染的，病人通过咳嗽、打喷嚏、高声喧哗等将带菌液体喷出体外，健康人吸入后就会被感染。据WHO的《2022年全球结核病报告》显示：2021年全球约有1060万结核病患者，比2020年增加4.5%；有160万人死于结核病，我国2021年估算的结核病新发患者数为78.0万。受新冠肺炎疫情的影响，预计2020年和2021年结核病作为单一传染源的死亡原因将降至第2位。2.结核杆菌与宿主免疫系统MTB是一种非常成功的细胞内病原体，与宿主共同进化。宿主免疫细胞被触发成不杀灭MTB，导致MTB的潜伏感染，其通过形成肉芽肿在宿主和病原体之间保持平衡。患者体内的潜伏期肺结核的再激活率从5到10%。宿主细胞不能抑制MTB生长导致肉芽肿病变，坏死的巨噬细胞死亡和炎性细胞募集增。这种宿主免疫力的退避反映了致病性分枝杆菌在宿主细胞内存活、存留的高度进化和多因子能力。MTB开发的逃避宿主天然免疫的复杂机制包括细胞溶质逃逸，抗菌肽的限制性生成，吞噬体成熟的阻断，细胞凋亡，炎性体激活和自噬的调节。3.结核病的预防图2.如何预防结核病1.控制传染源。早期发现传染源和彻底治愈涂阳肺结核病人是控制传染源的关键。对确诊的结核病人，应及时转至结核病防治机构，进行统一管理，并实行全程督导短程化学治疗(DOTS)。2.切断传播途径。结核菌主要通过呼吸道传播，患者和家属应佩戴一次性外科口罩；开窗通风，保持空气新鲜，可有效降低结核病传播；餐具煮沸消毒或用消毒液浸泡毒，同桌共餐时使用公筷；衣物、寝具、书籍等污染物可在烈日下暴晒进行杀菌。3.保护易感人群。进行卡介苗(BCG)接种：可使未受过结核菌感染者获得对结核病的特异免疫力；化学药物预防：对于高危人群，可以遵医嘱预防服用抗结核的化学药物；生活有规律：避免长期过劳和精神紧张，戒烟、饮食均衡，适当进行锻炼，增强抵抗力。4. 结核病的诊断及治疗1.体外诊断IVD世界卫生组织(WHO)推荐使用快速分子检测技术作为结核病的初始诊断方法，分子检测技术准确可靠，在早期发现结核病和耐药结核病方面发挥着重要作用，是终止结核病流行（END TB）策略中加强结核病实验室工作的重要内容。2021年，WHO推荐分子诊断技术的原则由特定技术类型推荐改为基于类别进行推荐，依据操作复杂程度和自动化水平对诊断技术进行分类，共批准6项用于结核病诊断和抗结核药物耐药性检测的分子诊断技术：l 低复杂程度自动化检测平台：赛沛Xpert MTB/XDRl 中等复杂程度自动化检测平台：雅培Abbott RealTime MTB &MTB RIF/INH、碧迪BD Max MDR-TB、罗氏cobas MTB & MTB-RIF/INH、海恩/布鲁克FluroType MTB & MTBDRl 高复杂程度尼：普洛Genoscholar PZA-TB检测 2.化学药物治疗临床上针对敏感结核分歧杆菌广泛采用的标准治疗方案由利福平、异烟肼、吡嗪酰胺和乙胺丁醇组成，其机理为杀菌和抑菌作用，具有较好的治疗效果。但目前，耐多药和广泛耐药结核分枝杆菌感染在世界范围内广泛流行。针对这一现象，WHO推荐用药不断推陈出新，从以往的注射药物治疗转为短程口服治疗，以缩短药物疗程，防止细菌耐药。此外，结核新药研发也取得很大的进展。抗结核新药(贝达喹啉、普瑞玛尼、德拉马尼等)已进入临床使用，对于耐药结核治疗及缩短疗程具有良好的效果。包括 TBA-7371、 GSK-656、 OPC-167832、Telacebec、Delpazolid、Sutezolid、SQ-109等候选药物已经进入Ⅱ期临床试验。3.免疫治疗耐药结核病的治疗，除了开发新型抗结核药物外，提高宿主免疫应答水平和减轻宿主免疫炎性损伤的免疫治疗逐渐受到重视。● 细胞因子治疗通过注射或者雾化吸入的方式提高宿主体内特定细胞因子的含量，对宿主进行免疫干预来激发宿主的抗结核免疫应答。例如γ－干扰素、粒细胞－巨噬细胞集落刺激因子、、白细胞介素１/2等。● 免疫细胞治疗通过体内激活自体免疫效应细胞，或体外扩增自体或异体免疫效应细胞，然后回输给患者纠正免疫失衡和改善免疫功能，提高宿主抗感染应答水平。例如Ｖγ２Ｖδ２Ｔ细胞、固有自然杀伤Ｔ细胞等。4.治疗性疫苗实验性疫苗ID93+GLA-SE是由西雅图的Christopher B. Fox博士和Access to Advanced Health Institute（前身为传染病研究所）的科学家开发的。它是一种重组亚单位疫苗，由结核分枝杆菌的4种蛋白质与GLA-SE（一种免疫刺激佐剂）结合而成。这种冻干配方不需要冷藏，在注射前与无菌水混合。对于偏远地区来说，不需要冷链运输的高效疫苗将成为结束这一流行病的重要工具。5. 最新研究进展自新型冠状病毒全球大流行以来，结核分枝杆菌已成为仅次于SARS-CoV-2的第二大单一感染致死病原，同时感染结核分枝杆菌和艾滋病病毒的患者更是高危人群。近期，北京协和医院医院李永哲教授、石家庄市第五医院戴二黑教授团队发表于《感染杂志》（Journal of Infection）一项横断面研究，对成年结核病患者新冠灭活疫苗加强针的安全性和免疫原性进行分析。临床数据表明：尽管灭活疫苗加强针提高了结核病患者的SARS-CoV-2特异性抗体水平和中和活性，但结核病患者的体液免疫差于健康人群，可进行动态血清抗体监测以推断接种加强针的最佳时机，从而发挥疫苗的最大优势。同时，相对于第2剂灭活疫苗，加强接种可实现结核病患者广泛的体液免疫，尽管仍低于健康人群。而相对于野生毒株，Omicron BA.4/5的中和活性仍然较低，虽然两组人群均已接种第3剂COVID-19疫苗。Omicron亚变种的刺突蛋白RBD突变使其获得了突破性感染，并且能够逃避由COVID-19疫苗构建的免疫保护。因此，为Omicron变异株定制疫苗必不可少。让我们一起努力，对抗结核，守护健康!❒ 第七届宁波生物产业论坛暨BioDeveloper药研者大会大会名称丨第七届宁波生物产业论坛暨BioDeveloper药研者大会大会主题丨潮起甬南 · 破浪笃行大会时间丨2023年4月26-27日大会地点 | 浙江 · 宁海（喜来登酒店-桃源街道天明中路108号）大会规模 | 200+主办单位 | 中共宁海县委组织部、宁海县生物产业园管理中心承办单位 | 甲贝医药支持单位 | 中国生物工程学会、宁波市经信局、宁波市科技局、宁波市投资促进署、中共宁海县委统战部、宁波市医药行业协会、宁波体外诊断联盟、宁波股权交易中心、“科创中国”生物医药产业科技服务团、美国华人生物医药科技协会(CBA)媒体支持 | 佰傲谷BioValley、动脉网扫码报名（免费参会需审核）▽邀请辞本届论坛将以“潮起甬南，破浪笃行”为主题，汇聚政产学研等各路行业领袖专家。于暮春日，游宁海，凭栏远眺，闲谈些许求药故事。第七届宁波生物产业论坛暨BioDeveloper药研者大会将于4月26日-27日在浙江宁海举办。我们期待药物研发者们暂时放下严肃的“奋斗者”姿态，换一种风格、换一种情绪，在严谨的工作之余，重新认识一下并肩作战的朋友们，好好的交流一下当前与未来？风景几许？岂不美哉？推荐阅读：最新议程发布 | 第七届宁波生物产业论坛4月宁海召开！点击“阅读原文”，立即报名~

临床研究

2023-01-25

·BioSpace

Methicillin-Resistant Staphylococcus aureus Infection Pipeline Clinical Trials Featuring 25+ companies

New York, USA, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Methicillin-Resistant Staphylococcus aureus Infection Pipeline Clinical Trials Featuring 25+ companies| DelveInsight Methicillin-resistant Staphylococcus aureus (MRSA) is an infection caused by antibiotic-resistant strains of the pathogen Staphylococcus aureus. Rising incidence of Methicillin-resistant Staphylococcus aureus (MRSA) infections is creating health concerns among the population. Manufacturers are focusing on product development and launches for the treatment of Methicillin-resistant Staphylococcus aureus (MRSA). DelveInsight’s 'Methicillin-Resistant Staphylococcus aureus Infection Pipeline Insight 2023' report provides comprehensive global coverage of available, marketed, and pipeline methicillin-resistant Staphylococcusaureus infection therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the methicillin-resistant Staphylococcusaureus infection pipeline domain. Key Takeaways from the Methicillin-Resistant Staphylococcus aureus Infection Pipeline Report DelveInsight’s methicillin-resistant Staphylococcusaureus infection pipeline report depicts a robust space with 25+ companies and 28+ pipeline drugs for methicillin-resistant Staphylococcusaureus infection treatment. Key methicillin-resistant Staphylococcusaureus infection companies include Trellis Bioscience, LegoChem Biosciences, Aptorum Group, ContraFect, Crystalgenomics, Cellics Therapeutics, MicuRx, Oxford Antibiotic Group, Destiny Pharma, TSRL, Inc., TAXIS Pharmaceuticals, Basilea Pharmaceutica, Helperby Therapeutics, Akagera Medicines, Histogen, Alphamab Co. Ltd, Biocidium Pharmaceuticals, and others are evaluating novel methicillin-resistant Staphylococcusaureus infection drugs candidate to improve the treatment landscape. Promising methicillin-resistant Staphylococcusaureus infection pipeline therapies in various stages of development include TRL1068, Delpazolid, ALS 4, Teicoplanin inhalation, CG 400549, SAAP 148, Exebacase, Marinus, CTI 005, Iclaprim, MRX 4, MRX 7, XF-73, TXA709, ARV-1801, ACX-375C, ABX-605, IBT-V02, BCM-0184, Contezolid, TetramOX, Ceftobiprole, HY-004B8b, HY-005B8a, CG-549, Emricasan, KN043, and several others. Ceftobiprole medocaril, the prodrug of the active moiety ceftobiprole, is a cephalosporin antibiotic for intravenous administration, with rapid bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria. This includes methicillin-susceptible and resistant Staphylococcus aureus (MSSA, MRSA) and susceptible Pseudomonas spp. In October 2022, Basilea Pharmaceutica announced the results from Phase III ERADICATE study, evaluating ceftobiprole in the treatment of adult patients with bacterial bloodstream infections caused by Staphylococcus aureus. Results for the primary efficacy outcomes were consistent in key subgroups including in patients with MSSA or MRSA bloodstream infections at baseline, and in various categories of underlying conditions such as skin and skin structure infections, abdominal abscesses, chronic dialysis, septic arthritis, osteomyelitis, definite right-sided infective endocarditis and in patients with persistent SAB. Basilea also planned to submit a New Drug Application (NDA) for ceftobiprole to the US Food and Drug Administration (FDA) around year-end 2022. Exebacase (CF-301) being developed by ContraFect Corporation is a lysin with potent activity against Staphylococcus aureus ("Staph aureus"). Exebacase has the potential to be the first-in-class of a new treatment for patients with Staph aureus bacteremia. The FDA has granted Breakthrough Therapy designation to exebacase for the treatment of MRSA bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to SOC antistaphylococcal antibiotics in adult patients, based on the final data from the Phase II superiority trial of exebacase. In July 2022, Destiny Pharma plc announced that it had received an award from the Cystic Fibrosis Foundation. The research project will establish the potential of the Company’s proprietary XF-73 drug as a novel treatment for cystic fibrosis patients infected with methicillin-resistant Staphylococcus aureus (MRSA). CTI-005 is for the treatment of Methicillin Resistance Staphylococcus Aureus (MRSA) Pneumonia and has been granted IND allowance from the US FDA. The potent RBC-NS has the membrane lipids and receptors that a normal red blood cell has, however, the high surface-volume ratio of the RBC-NS allows it to act as a decoy. This characteristic allows the RBC-NS to bind and neutralize toxins, auto-antibodies, and bacterial infections. The pore-forming toxins emitted by MRSA can be effectively absorbed and neutralized by RBC-NS. Request a sample and discover the recent advances in methicillin-resistant Staphylococcusaureus infection treatment drugs @ Methicillin-Resistant Staphylococcus aureus Infection Pipeline Report The methicillin-resistant Staphylococcusaureus infection pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage methicillin-resistant Staphylococcusaureus infection products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the methicillin-resistant Staphylococcusaureus infection pipeline landscape. Methicillin-Resistant Staphylococcus aureus Infection Overview Methicillin-resistant Staphylococcus aureus (MRSA) infections are caused by bacteria that have attained resistance from several antibiotics that treat diseases caused by Staphylococcus bacteria. The common patients of Methicillin-resistant Staphylococcus aureus (MRSA) infections are patients that have been in hospitals or healthcare settings for a long duration where the bacteria is found commonly. MRSA infections are known as healthcare-associated MRSA (HA-MRSA) if infected in hospitals. Such infections can spread to healthcare workers through invasive procedures, which are further transmitted to several patients by touching and operating with bare hands. Other MRSA infections occur in a considerable population of healthy people. People associated with community-associated MRSA (CA-MRSA) show symptoms appearing as painful skin boils. It further spreads through physical contact between individuals. The population at higher risk includes people surrounded by a significant number of people and childcare workers. MRSA infections might look like red bumps, pimples, or spider bites, accompanied by pus and fever. Find out more about methicillin-resistant Staphylococcusaureus infection treatment drugs @ Drugs for Methicillin-Resistant Staphylococcus aureus Infection Treatment A snapshot of the Methicillin-Resistant Staphylococcus aureus Infection pipeline drugs mentioned in the report: Drug Company Phase MoA RoA Ceftobiprole Basilea Pharmaceutica Phase III Cell wall inhibitors; Peptidyltransferase inhibitors Intravenous CG 549 CrystalGenomics Phase II Enoyl-ACP reductase inhibitors; Fatty acid synthase expression inhibitors; Fatty acid synthetase complex inhibitors Oral BCM-0184 Biocidium Pharmaceuticals Phase I NA Oral/Topical TRL1068 Trellis Bioscience Phase I Bacterial biofilm inhibitors Intravenous ALS 4 Aptorum Group Phase I Bacterial virulence inhibitors Oral EVX-B1 Evaxion Biotech Preclinical Immunostimulants NA Emricasan Histogen Preclinical Apoptosis inhibitors; Caspase inhibitors NA TarO inhibitor Prokaryotics Discovery Cell membrane inhibitors; Cell wall inhibitors NA Learn more about the emerging methicillin-resistant Staphylococcusaureus infection pipeline therapies @ Methicillin-Resistant Staphylococcus aureus Infection Clinical Trials Methicillin-Resistant Staphylococcus aureus Infection Therapeutics Assessment The methicillin-resistant Staphylococcus aureus infection pipeline report proffers an integral view of methicillin-resistant Staphylococcusaureus infection emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Methicillin-Resistant Staphylococcus aureus Infection Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Pre-clinical, Discovery, Discontinued, Inactive, Phase I, Phase II, Phase III Therapeutics AssessmentBy Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical. Therapeutics AssessmentBy Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy Therapeutics AssessmentBy Mechanism of Action: Cell wall inhibitors; Peptidyltransferase inhibitors, Enoyl-ACP reductase inhibitors; Fatty acid synthase expression inhibitors; Fatty acid synthetase complex inhibitors, Bacterial biofilm inhibitors, Bacterial virulence inhibitors, Immunostimulants, Apoptosis inhibitors; Caspase inhibitors, Cell membrane inhibitors; Cell wall inhibitors Key Methicillin-Resistant Staphylococcus aureus Infection Companies: Trellis Bioscience, LegoChem Biosciences, Aptorum Group, ContraFect, Crystalgenomics, Cellics Therapeutics, MicuRx, Oxford Antibiotic Group, Destiny Pharma, TSRL, Inc., TAXIS Pharmaceuticals, Basilea Pharmaceutica, Helperby Therapeutics, Akagera Medicines, Histogen, Alphamab Co. Ltd, Biocidium Pharmaceuticals, and others. Key Methicillin-Resistant Staphylococcus aureus Infection Pipeline Therapies: TRL1068, Delpazolid, ALS 4, Teicoplanin inhalation, CG 400549, SAAP 148, Exebacase, Marinus, CTI 005, Iclaprim, MRX 4, MRX 7, XF-73, TXA709, ARV-1801, ACX-375C, ABX-605, IBT-V02, BCM-0184, Contezolid, TetramOX, Ceftobiprole, HY-004B8b, HY-005B8a, CG-549, Emricasan, KN043, and others. Dive deep into rich insights for new drugs for methicillin-resistant Staphylococcusaureus infection treatment; visit @ Methicillin-Resistant Staphylococcus aureus Infection Drugs Table of Contents 1. Methicillin-Resistant Staphylococcus aureus Infection Pipeline Report Introduction 2. Methicillin-Resistant Staphylococcus aureus Infection Pipeline Report Executive Summary 3. Methicillin-Resistant Staphylococcus aureus Infection Pipeline: Overview 4. Analytical Perspective In-depth Commercial Assessment 5. Methicillin-Resistant Staphylococcus aureus Infection Pipeline Therapeutics 6. Methicillin-Resistant Staphylococcus aureus Infection Pipeline: Late Stage Products (Pre-registration) 7. Methicillin-Resistant Staphylococcus aureus Infection Pipeline: Late Stage Products (Phase III) 7.1 Ceftobiprole: Basilea Pharmaceutica 8. Methicillin-Resistant Staphylococcus aureus Infection Pipeline: Mid Stage Products (Phase II) 8.1 CG549: CrystalGenomics 9. Methicillin-Resistant Staphylococcus aureus Infection Pipeline: Early Stage Products (Phase I) 9.1 TRL1068: Trellis Bioscience 10. Methicillin-Resistant Staphylococcus aureus Infection Pipeline Therapeutics Assessment 11. Inactive Products in the Methicillin-Resistant Staphylococcus aureus Infection Pipeline 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Key Companies 14. Key Products in the Methicillin-Resistant Staphylococcus aureus Infection Pipeline 15. Unmet Needs 16. Market Drivers and Barriers 17. Future Perspectives and Conclusion 18. Analyst Views 19. Appendix For further information on the methicillin-resistant Staphylococcusaureus infection pipeline therapeutics, reach out @ Methicillin-Resistant Staphylococcus aureus Infection Treatment Drugs Related Reports Methicillin-Resistant Staphylococcus aureus Epidemiology Forecast Methicillin-Resistant Staphylococcus aureus Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the methicillin-resistant Staphylococcusaureus epidemiology trends. Methicillin-Resistant Staphylococcus aureus Infection Market Methicillin-Resistant Staphylococcus aureus Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key methicillin-resistant Staphylococcusaureus infection companies, including Trellis Bioscience, LegoChem Biosciences, Aptorum Group, Allergan, iNtRON Biotechnology, Neupharma, ImmuPharma, Lytix Biopharma, CrystalGenomics, AIMM Therapeutics, among others. Staphylococcus aureus Bacteremia Pipeline Staphylococcus aureus Bacteremia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug pro including clinical and non-clinical stage products, and the key Staphylococcus aureus Bacteremia companies, including ContraFect, Armata Pharmaceuticals, iNtRON Biotechnology, Durata Therapeutics, Cipher Pharmaceuticals, XBiotech, Basilea Pharmaceutica, Genentech, among others. Hospital Acquired Methicillin-Resistant Staphylococcus aureus Infections Pipeline Hospital Acquired Methicillin-Resistant Staphylococcus aureus Infections Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug pro including clinical and non-clinical stage products, and the key Hospital Acquired Methicillin-Resistant Staphylococcus aureus Infections companies, including Trellis Bioscience, LegoChem Biosciences, Aptorum Group, Allergan, iNtRON Biotechnology, Neupharma, ImmuPharma, Lytix Biopharma, CrystalGenomics, AIMM Therapeutics, among others. Other Trending Reports Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Brain Cancer Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market Related Healthcare Services Healthcare Consulting Healthcare Competitive Intelligence Services Healthcare Asset Prioritization Services About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. Connect with us atLinkedIn Contact Us Shruti Thakur info@delveinsight.com +1(919)321-6187

临床3期临床2期临床结果

100 项与 Delpazolid 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB13077

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脓肿分枝杆菌感染	临床2期	韩国	LigaChem Biosciences, Inc.	2024-01-16
耐甲氧西林金黄色葡萄球菌引起的菌血症	临床2期	美国	LigaChem Biosciences, Inc.	2022-04-26
肺结核	临床2期	美国	LigaChem Biosciences, Inc.	2016-12-10
社区获得性肺炎	临床1期	中国	广西新为医药科技有限公司	2022-01-30
结核	临床1期	中国	诺迈西（上海）医药科技有限公司	2019-05-09
软组织感染	临床1期	中国	广西新为医药科技有限公司	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04550832 (DECODE, CTgov)	临床2期	肺结核	76	Moxifloxacin+Bedaquiline+Delamanid (Arm1(D0))	鬱鬱遞鹹蓋衊蓋遞繭繭 = 蓋積顧艱構鑰廠積廠淵網窪壓襯鏇選膚顧構廠 (廠壓餘觸製願鏇齋夢醖, 遞範鏇鬱願範鑰衊齋壓 ~ 鹽壓鹽簾觸選顧糧鹹鹹) 更多	-	2024-10-28
				Moxifloxacin+Bedaquiline+Delpazolid+Delamanid (Arm2(D400))	鬱鬱遞鹹蓋衊蓋遞繭繭 = 選齋醖憲壓壓夢鑰繭積網窪壓襯鏇選膚顧構廠 (廠壓餘觸製願鏇齋夢醖, 醖襯膚顧醖簾醖遞廠構 ~ 廠遞鬱鏇糧齋簾網鹹製) 更多
NCT04939779 (Pubmed \| Transl Clin Pharmacol)	临床1期	-	-	Batch No. 3183817R (test drug)	膚積窪選淵製廠蓋簾蓋(襯繭積顧廠鏇顧餘築網): GMR = 1.029 (90% CI, 0.8 ~ 1.25)	积极	2024-01-01
				Batch No. 1650006 (reference drug)
NCT02882789 (Pubmed \| Clin Ther)	临床1期	-	36	LCB01-0371	壓淵憲顧廠選壓淵醖糧(鑰網繭艱鹹醖衊夢齋製) = 築鹹範齋觸醖顧鏇餘鬱鏇憲糧網範製壓積醖構 (糧糧願壓顧鏇網糧製構 ) 更多	-	2019-01-01